Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines

R. Michael Tuttle; Robert I. Haddad; Douglas W. Ball; David Byrd; Paxton Dickson; Quan Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P. Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M. Lamonica; William M. Lydiatt; Judith McCaffrey; Jeffrey F. Moley; Lee Parks; Christopher D. Raeburn; John A. Ridge; Matthew D. Ringel; Randall P. Scheri; Jatin P. Shah; Steven I. Sherman; Cord Sturgeon; Steven G. Waguespack; Thomas N. Wang; Lori J. Wirth; Karin G. Hoffmann; Miranda Hughes

doi:10.6004/jnccn.2014.0169

Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines

R. Michael Tuttle
, Robert I. Haddad
, Douglas W. Ball
, David Byrd
, Paxton Dickson
, Quan Yang Duh
, Hormoz Ehya
, Megan Haymart
, Carl Hoh
, Jason P. Hunt
, Andrei Iagaru
, Fouad Kandeel
, Peter Kopp
, Dominick M. Lamonica
, William M. Lydiatt
, Judith McCaffrey
, Jeffrey F. Moley
, Lee Parks
, Christopher D. Raeburn
, John A. Ridge

Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann, Miranda Hughes

Pathology

Memorial Sloan-Kettering Cancer Center
Dana-Farber/Brigham and Women's Cancer Center
Johns Hopkins University
Seattle Cancer Care Alliance
University of Tennessee Health Science Center
University of California at San Francisco
University of Michigan, Ann Arbor
University of California at San Diego
University of Utah
Stanford University
City of Hope National Medical Center
Northwestern University
Roswell Park Cancer Institute
University of Nebraska Medical Center
University of South Florida
Washington University St. Louis
Vanderbilt University
University of Colorado Cancer Center
Fox Chase Cancer Center
Ohio State University
Duke University
University of Texas MD Anderson Cancer Center
University of Alabama at Birmingham
Massachusetts General Hospital Cancer Center
National Comprehensive Cancer Network

Research output: Contribution to journal › Article › peer-review

150 Scopus citations

Abstract

These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.

Original language	English
Pages (from-to)	1671-1680
Number of pages	10
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	12
Issue number	12
DOIs	https://doi.org/10.6004/jnccn.2014.0169
State	Published - Dec 1 2014

Keywords

Adenocarcinoma/drug therapy
Anilides/therapeutic use
Carcinoma, Neuroendocrine
Guidelines as Topic
Humans
Neoplasm Metastasis
Niacinamide/analogs & derivatives
Phenylurea Compounds/therapeutic use
Protein Kinase Inhibitors/therapeutic use
Pyridines/therapeutic use
Sorafenib
Thyroid Neoplasms/drug therapy

Access to Document

10.6004/jnccn.2014.0169

Cite this

Tuttle, R. M., Haddad, R. I., Ball, D. W., Byrd, D., Dickson, P., Duh, Q. Y., Ehya, H., Haymart, M., Hoh, C., Hunt, J. P., Iagaru, A., Kandeel, F., Kopp, P., Lamonica, D. M., Lydiatt, W. M., McCaffrey, J., Moley, J. F., Parks, L., Raeburn, C. D., ... Hughes, M. (2014). Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : JNCCN, 12(12), 1671-1680. https://doi.org/10.6004/jnccn.2014.0169

@article{ecbbf331b42c4cab9db727d6a97ddaa6,

title = "Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines",

abstract = "These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on {"}Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer{"} was added to the NCCN Guidelines to assist with using these novel targeted agents.",

keywords = "Adenocarcinoma/drug therapy, Anilides/therapeutic use, Carcinoma, Neuroendocrine, Guidelines as Topic, Humans, Neoplasm Metastasis, Niacinamide/analogs \& derivatives, Phenylurea Compounds/therapeutic use, Protein Kinase Inhibitors/therapeutic use, Pyridines/therapeutic use, Sorafenib, Thyroid Neoplasms/drug therapy",

author = "Tuttle, \{R. Michael\} and Haddad, \{Robert I.\} and Ball, \{Douglas W.\} and David Byrd and Paxton Dickson and Duh, \{Quan Yang\} and Hormoz Ehya and Megan Haymart and Carl Hoh and Hunt, \{Jason P.\} and Andrei Iagaru and Fouad Kandeel and Peter Kopp and Lamonica, \{Dominick M.\} and Lydiatt, \{William M.\} and Judith McCaffrey and Moley, \{Jeffrey F.\} and Lee Parks and Raeburn, \{Christopher D.\} and Ridge, \{John A.\} and Ringel, \{Matthew D.\} and Scheri, \{Randall P.\} and Shah, \{Jatin P.\} and Sherman, \{Steven I.\} and Cord Sturgeon and Waguespack, \{Steven G.\} and Wang, \{Thomas N.\} and Wirth, \{Lori J.\} and Hoffmann, \{Karin G.\} and Miranda Hughes",

note = "Publisher Copyright: {\textcopyright} JNCCN-Journal of the National Comprehensive Cancer Network.",

year = "2014",

month = dec,

day = "1",

doi = "10.6004/jnccn.2014.0169",

language = "English",

volume = "12",

pages = "1671--1680",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Harborside Press",

number = "12",

}

Tuttle, RM, Haddad, RI, Ball, DW, Byrd, D, Dickson, P, Duh, QY, Ehya, H, Haymart, M, Hoh, C, Hunt, JP, Iagaru, A, Kandeel, F, Kopp, P, Lamonica, DM, Lydiatt, WM, McCaffrey, J, Moley, JF, Parks, L, Raeburn, CD, Ridge, JA, Ringel, MD, Scheri, RP, Shah, JP, Sherman, SI, Sturgeon, C, Waguespack, SG, Wang, TN, Wirth, LJ, Hoffmann, KG & Hughes, M 2014, 'Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 12, no. 12, pp. 1671-1680. https://doi.org/10.6004/jnccn.2014.0169

TY - JOUR

T1 - Thyroid carcinoma, version 2.2014

T2 - Featured updates to the NCCN guidelines

AU - Tuttle, R. Michael

AU - Haddad, Robert I.

AU - Ball, Douglas W.

AU - Byrd, David

AU - Dickson, Paxton

AU - Duh, Quan Yang

AU - Ehya, Hormoz

AU - Haymart, Megan

AU - Hoh, Carl

AU - Hunt, Jason P.

AU - Iagaru, Andrei

AU - Kandeel, Fouad

AU - Kopp, Peter

AU - Lamonica, Dominick M.

AU - Lydiatt, William M.

AU - McCaffrey, Judith

AU - Moley, Jeffrey F.

AU - Parks, Lee

AU - Raeburn, Christopher D.

AU - Ridge, John A.

AU - Ringel, Matthew D.

AU - Scheri, Randall P.

AU - Shah, Jatin P.

AU - Sherman, Steven I.

AU - Sturgeon, Cord

AU - Waguespack, Steven G.

AU - Wang, Thomas N.

AU - Wirth, Lori J.

AU - Hoffmann, Karin G.

AU - Hughes, Miranda

PY - 2014/12/1

Y1 - 2014/12/1

N2 - These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.

AB - These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.

KW - Adenocarcinoma/drug therapy

KW - Anilides/therapeutic use

KW - Carcinoma, Neuroendocrine

KW - Guidelines as Topic

KW - Humans

KW - Neoplasm Metastasis

KW - Niacinamide/analogs & derivatives

KW - Phenylurea Compounds/therapeutic use

KW - Protein Kinase Inhibitors/therapeutic use

KW - Pyridines/therapeutic use

KW - Sorafenib

KW - Thyroid Neoplasms/drug therapy

UR - https://www.scopus.com/pages/publications/84918790948

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000346190900005&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.6004/jnccn.2014.0169

DO - 10.6004/jnccn.2014.0169

M3 - Article

C2 - 25505208

SN - 1540-1405

VL - 12

SP - 1671

EP - 1680

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 12

ER -

Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this